Our experimental results suggested that MeCP2 promoted breast cancer cell proliferation and inhibited apoptosis through promoting ubiquitination-mediated P53 degradation by suppressing RPL11 and RPL5 expression. Here, RPL11 is linked to breast carcinoma.